Literature DB >> 15561843

Degradation of human antimicrobial peptide LL-37 by Staphylococcus aureus-derived proteinases.

Magdalena Sieprawska-Lupa1, Piotr Mydel, Katarzyna Krawczyk, Kinga Wójcik, Magdalena Puklo, Boguslaw Lupa, Piotr Suder, Jerzy Silberring, Matthew Reed, Jan Pohl, William Shafer, Fionnuala McAleese, Timothy Foster, Jim Travis, Jan Potempa.   

Abstract

Cathelicidin LL-37 is one of the few human bactericidal peptides with potent antistaphylococcal activity. In this study we examined the susceptibility of LL-37 to proteolytic degradation by two major proteinases produced by Staphylococcus aureus, a metalloproteinase (aureolysin) and a glutamylendopeptidase (V8 protease). We found that aureolysin cleaved and inactivated LL-37 in a time- and concentration-dependent manner. Analysis of the generated fragments by mass spectroscopy revealed that the initial cleavage of LL-37 by aureolysin occurred between the Arg19-Ile20, Arg23-Ile24, and Leu31-Val32 peptide bonds, instantly annihilating the antibacterial activity of LL-37. In contrast, the V8 proteinase hydrolyzed efficiently only the Glu16-Phe17 peptide bond, rendering the C-terminal fragment refractory to further degradation. This fragment (termed LL-17-37) displayed antibacterial activity against S. aureus at a molar level similar to that of the full-length LL-37 peptide, indicating that the antibacterial activity of LL-37 resides in the C-terminal region. In keeping with LL-37 degradation by aureolysin, S. aureus strains that produce significant amounts of this metalloprotease were found to be less susceptible to LL-17-37 than strains expressing no aureolysin activity. Taken together, these data suggest that aureolysin production by S. aureus contributes to the resistance of this pathogen to the innate immune system of humans mediated by LL-37.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15561843      PMCID: PMC529204          DOI: 10.1128/AAC.48.12.4673-4679.2004

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  50 in total

1.  Cutaneous injury induces the release of cathelicidin anti-microbial peptides active against group A Streptococcus.

Authors:  R A Dorschner; V K Pestonjamasp; S Tamakuwala; T Ohtake; J Rudisill; V Nizet; B Agerberth; G H Gudmundsson; R L Gallo
Journal:  J Invest Dermatol       Date:  2001-07       Impact factor: 8.551

2.  Transfer of a cathelicidin peptide antibiotic gene restores bacterial killing in a cystic fibrosis xenograft model.

Authors:  R Bals; D J Weiner; R L Meegalla; J M Wilson
Journal:  J Clin Invest       Date:  1999-04       Impact factor: 14.808

3.  Augmentation of innate host defense by expression of a cathelicidin antimicrobial peptide.

Authors:  R Bals; D J Weiner; A D Moscioni; R L Meegalla; J M Wilson
Journal:  Infect Immun       Date:  1999-11       Impact factor: 3.441

4.  Inhibition of neutrophil elastase prevents cathelicidin activation and impairs clearance of bacteria from wounds.

Authors:  A M Cole; J Shi; A Ceccarelli; Y H Kim; A Park; T Ganz
Journal:  Blood       Date:  2001-01-01       Impact factor: 22.113

5.  Loss of clumping factor B fibrinogen binding activity by Staphylococcus aureus involves cessation of transcription, shedding and cleavage by metalloprotease.

Authors:  F M McAleese; E J Walsh; M Sieprawska; J Potempa; T J Foster
Journal:  J Biol Chem       Date:  2001-06-08       Impact factor: 5.157

6.  Staphylococcus aureus agr genotypes with enterotoxin production capabilities can resist neutrophil bactericidal activity.

Authors:  I K Mullarky; C Su; N Frieze; Y H Park; L M Sordillo
Journal:  Infect Immun       Date:  2001-01       Impact factor: 3.441

7.  Human cathelicidin, hCAP-18, is processed to the antimicrobial peptide LL-37 by extracellular cleavage with proteinase 3.

Authors:  O E Sørensen; P Follin; A H Johnsen; J Calafat; G S Tjabringa; P S Hiemstra; N Borregaard
Journal:  Blood       Date:  2001-06-15       Impact factor: 22.113

8.  Isolation and characterization of human beta -defensin-3, a novel human inducible peptide antibiotic.

Authors:  J Harder; J Bartels; E Christophers; J M Schroder
Journal:  J Biol Chem       Date:  2000-11-20       Impact factor: 5.157

9.  Bactericidal activity of mammalian cathelicidin-derived peptides.

Authors:  S M Travis; N N Anderson; W R Forsyth; C Espiritu; B D Conway; E P Greenberg; P B McCray; R I Lehrer; M J Welsh; B F Tack
Journal:  Infect Immun       Date:  2000-05       Impact factor: 3.441

10.  Staphylococcus aureus resistance to human defensins and evasion of neutrophil killing via the novel virulence factor MprF is based on modification of membrane lipids with l-lysine.

Authors:  A Peschel; R W Jack; M Otto; L V Collins; P Staubitz; G Nicholson; H Kalbacher; W F Nieuwenhuizen; G Jung; A Tarkowski; K P van Kessel; J A van Strijp
Journal:  J Exp Med       Date:  2001-05-07       Impact factor: 14.307

View more
  193 in total

Review 1.  Epithelial antimicrobial defence of the skin and intestine.

Authors:  Richard L Gallo; Lora V Hooper
Journal:  Nat Rev Immunol       Date:  2012-06-25       Impact factor: 53.106

2.  Temperature-dependent production of various PlcR-controlled virulence factors in Bacillus weihenstephanensis strain KBAB4.

Authors:  A Réjasse; N Gilois; I Barbosa; E Huillet; C Bevilacqua; S Tran; N Ramarao; L P Stenfors Arnesen; V Sanchis
Journal:  Appl Environ Microbiol       Date:  2012-02-03       Impact factor: 4.792

3.  The oligo-acyl lysyl antimicrobial peptide C₁₂K-2β₁₂ exhibits a dual mechanism of action and demonstrates strong in vivo efficacy against Helicobacter pylori.

Authors:  Morris O Makobongo; Hanan Gancz; Beth M Carpenter; Dennis P McDaniel; D Scott Merrell
Journal:  Antimicrob Agents Chemother       Date:  2011-11-07       Impact factor: 5.191

4.  Resistance to antimicrobial peptides and stress response in Mycoplasma pulmonis.

Authors:  Lina Fassi Fehri; Pascal Sirand-Pugnet; Géraldine Gourgues; Gwenaël Jan; Henri Wróblewski; Alain Blanchard
Journal:  Antimicrob Agents Chemother       Date:  2005-10       Impact factor: 5.191

5.  Cationic antimicrobial peptide resistance in Neisseria meningitidis.

Authors:  Yih-Ling Tzeng; Karita D Ambrose; Susu Zughaier; Xiaoliu Zhou; Yoon K Miller; William M Shafer; David S Stephens
Journal:  J Bacteriol       Date:  2005-08       Impact factor: 3.490

6.  Methicillin-resistant Staphylococcus aureus bacterial nitric-oxide synthase affects antibiotic sensitivity and skin abscess development.

Authors:  Nina M van Sorge; Federico C Beasley; Ivan Gusarov; David J Gonzalez; Maren von Köckritz-Blickwede; Sabina Anik; Andrew W Borkowski; Pieter C Dorrestein; Evgeny Nudler; Victor Nizet
Journal:  J Biol Chem       Date:  2013-01-15       Impact factor: 5.157

7.  Midkine is expressed and differentially processed during chronic obstructive pulmonary disease exacerbations and ventilator-associated pneumonia associated with Staphylococcus aureus infection.

Authors:  Helena M Linge; Cecilia Andersson; Sara L Nordin; Anders I Olin; Ann-Cathrine Petersson; Matthias Mörgelin; Amanda Welin; Johan Bylund; Leif Bjermer; Jonas Erjefält; Arne Egesten
Journal:  Mol Med       Date:  2013-09-30       Impact factor: 6.354

8.  Induction of the Cpx envelope stress pathway contributes to Escherichia coli tolerance to antimicrobial peptides.

Authors:  Bianca Audrain; Lionel Ferrières; Amira Zairi; Guillaume Soubigou; Curtis Dobson; Jean-Yves Coppée; Christophe Beloin; Jean-Marc Ghigo
Journal:  Appl Environ Microbiol       Date:  2013-10-04       Impact factor: 4.792

Review 9.  Interaction of host and Staphylococcus aureus protease-system regulates virulence and pathogenicity.

Authors:  Vigyasa Singh; Ujjal Jyoti Phukan
Journal:  Med Microbiol Immunol       Date:  2018-11-27       Impact factor: 3.402

10.  The plasmid-encoded regulator activates factors conferring lysozyme resistance on enteropathogenic Escherichia coli strains.

Authors:  Nina Salinger; Bashkim Kokona; Robert Fairman; Iruka N Okeke
Journal:  Appl Environ Microbiol       Date:  2008-11-07       Impact factor: 4.792

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.